

UNITED STAT DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Westington D.C. 20231

APPLICATION NUMBER FIRST NAMED APPLICANT ATTY, DOCKET NO. 08/902,516 07/29/97 HOO W P-IM2442 EXAMINER HM11/0608 ROBERT T RAMOS CAMPBELL & FLORES SUITE 700 4370 LA JOLLA VILLAGE DRIVE 1646 SAN DIEGO CA 92122 06/08/98 This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS OFFICE ACTION SUMMARY Responsive to communication(s) filed on This action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 D.C. 11; 453 O.G. 213. A shortened statutory period for response to this action is set to expire _ month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a). **Disposition of Claims** Claim(s) is/are pending in the application. Of the above, claim(s) is/are withdrawn from consideration. Claim(s)_ is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) _ are subject to restriction or election requirement. **Application Papers** See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed on _ is/are objected to by the Examiner. The proposed drawing correction, filed on _is 🔲 approved 🔲 disapproved. The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been ____ received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received: Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) Notice of Reference Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). Interview Summary, PTO-413 Notice of Draftperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152

-SEE OFFICE ACTION ON THE FOLLOWING PAGES--

5

10

15

20

25

Part III: Detailed Office Action

Notice: Effective February 7, 1998, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1646.

Election of Species Requirement:

Claims 1, 19, 36 and 46 are generic to a plurality of disclosed patentably distinct species comprising:

- (a) patentably distinct species of immunomodulatory molecules, selected from the group consisting of heat shock proteins, the various cytokines listed, e.g. in claim 5;
- (b) patentably distinct cell types, selected from the group consisting of prokaryotic cells, fibroblasts, and the various tumor cell types listed in claim 11; and
- (c) disease associated antigens selected from the group consisting of the specific antigens listed in claim 16 and TCR derived peptide (claim 17)
- Applicant is required under 35 U.S.C. 121 to elect a single disclosed ultimate species (i.e. a single species of immunomodulatory molecule, cell type and disease associated antigen), even though this requirement is traversed.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Advisory Information:

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Lorraine M. Spector, whose telephone number is (703) 308-1793. Dr. Spector can normally be reached Monday through Friday, 8:00 A.M. to 4:30 P.M.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Stephen Walsh, can be reached at (703)308-2957.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist at telephone number (703) 308-0196.

Certain papers related to this application may be submitted to Group 1800 by facsimile transmission. Papers should be faxed to Group 1800 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Official papers filed by fax should be directed to (703) 305-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. **Please** advise the Examiner at the telephone number above when an informal fax is being transmitted.

25

5

10

15

20

30

35

Conaine Spector, Ph.D.
Primary Examiner

LMS 902516.spp 6/5/98